| Effect of lipid modification on progression of coronary calcification. | |
| | |
MedLine Citation:
|
PMID: 16251246 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Coronary artery calcification (CAC) reflects the anatomic presence of coronary atherosclerosis and the relative burden of coronary artery disease (CAD). Higher levels of CAC are seen in the presence of CAD risk factors, older age, and chronic kidney disease. The lipid profile (primarily low HDL cholesterol, elevated triglycerides, elevated LDL cholesterol, and elevated total cholesterol) are important factors in the calcification process. The annual progression of CAC can be reduced from 25 to 30% to 0 to 6% with LDL cholesterol reduction caused by statins and possibly sevelamer. At treated LDL cholesterol levels somewhere below 100 mg/dl, several sources of data suggest the anatomic burden of CAD, including CAC, regresses. Additional supportive studies indicate that carotid intimal medial thickness and the volume of coronary atheroma also can be reduced by LDL cholesterol reduction in concert with elevation of HDL cholesterol. This article reviews the data in support of altering the natural history of CAC with lipid modification. |
| | |
Authors:
|
Peter A McCullough |
Related Documents
:
|
2179786 - Cardiovascular implications of estrogen replacement therapy. 10645516 - A comparative study of policosanol versus acipimox in patients with type ii hypercholes... 6796096 - Reduced ldl- and increased hdl-apoproteins in patients with hypercholesterolaemia under... 21139126 - The macrobiotic diet in chronic disease. 12048126 - Spontaneous atherosclerosis in the proximal aorta of lpa transgenic mice on a normal diet. 15913196 - Effects of delayed placement on intestinal characteristics in turkey poults. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of the American Society of Nephrology : JASN Volume: 16 Suppl 2 ISSN: 1046-6673 ISO Abbreviation: J. Am. Soc. Nephrol. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-10-27 Completed Date: 2006-02-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9013836 Medline TA: J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: S115-9 Citation Subset: IM |
Affiliation:
|
Division of Nutrition and Preventive Medicine, William Beaumont Hospital, 4949 Coolidge, Royal Oak, MI 48073, USA. pmc975@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Calcinosis
/
blood*,
complications Cholesterol, HDL / blood Cholesterol, LDL / blood* Coronary Artery Disease / blood*, complications Disease Progression Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hypercholesterolemia / complications, drug therapy* Kidney Failure, Chronic / complications* |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Control of hyperphosphatemia among patients with ESRD.
Next Document: Strategies for improving long-term survival in patients with ESRD.